Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics Inc (DRMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,735
  • Shares Outstanding, K 2,041
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +52,131.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +36.00%
on 12/19/24
1.4500 -6.21%
on 12/09/24
+0.2591 (+23.54%)
since 11/26/24
3-Month
1.0000 +36.00%
on 12/19/24
1.6899 -19.52%
on 09/30/24
-0.1900 (-12.26%)
since 09/26/24
52-Week
1.0000 +36.00%
on 12/19/24
13.3500 -89.81%
on 01/05/24
-7.4900 (-84.63%)
since 12/26/23

Most Recent Stories

More News
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -

DRMAW : 0.0138 (-6.12%)
DRMA : 1.3600 (+1.49%)
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -

DRMAW : 0.0138 (-6.12%)
DRMA : 1.3600 (+1.49%)
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected in March 2025 -

DRMAW : 0.0138 (-6.12%)
DRMA : 1.3600 (+1.49%)
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

- Topline results expected in the second half of 2022 -

DRMA : 1.3600 (+1.49%)
Dermata to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 1.3600 (+1.49%)
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA;...

DRMA : 1.3600 (+1.49%)
DRMAW : 0.0138 (-6.12%)
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...

DRMA : 1.3600 (+1.49%)
DRMAW : 0.0138 (-6.12%)
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...

DRMA : 1.3600 (+1.49%)
DRMAW : 0.0138 (-6.12%)
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...

DRMA : 1.3600 (+1.49%)
DRMAW : 0.0138 (-6.12%)
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 1.3600 (+1.49%)

Business Summary

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

See More

Key Turning Points

3rd Resistance Point 1.5367
2nd Resistance Point 1.4733
1st Resistance Point 1.4167
Last Price 1.3600
1st Support Level 1.2967
2nd Support Level 1.2333
3rd Support Level 1.1767

See More

52-Week High 13.3500
Fibonacci 61.8% 8.6323
Fibonacci 50% 7.1750
Fibonacci 38.2% 5.7177
Last Price 1.3600
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar